Topical corticosteroid for treatment of hand osteoarthritis

Phase 3

Completed

• Conditions: Hand osteoarthritis; Musculoskeletal - Osteoarthritis

• Registration Number: ACTRN12620000599976
• Lead Sponsor: Flavia Cicuttini

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-05-22
• Study Completion: 2022-05-18
• Last Update Posted: 16 October 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 106

Inclusion Criteria

1. Participants aged >40 years with symptomatic radiological hand osteoarthritis;
2. Pain score of at least 40 on a 100 mm visual analogue scale and radiological OA (Kellgren and Lawrence grade >=2) in >=1 joint;
3. Stable analgesic requirements (including non-steroidal anti-inflammatory drugs) for at least 4 weeks, stable doses of chondroitin or glucosamine for 4 months, no corticosteroids via any route for at least 3 months.

Exclusion Criteria

1. Concomitant rheumatic disease, inflammatory joint disease, psoriatic arthritis, ankylosing spondylitis, or gout;
2. Allergic reaction to other medicines containing betamethasone dipropionate, any other corticosteroid(s), or any of the ingredients of Diprosone OV ointment (i.e. betamethasone as dipropionate, propylene glycol, white beeswax, propylene glycol monostearate, and soft white paraffin);
3. Contraindication to topical corticosteroids (e.g. untreated bacterial, fungal, or viral skin lesions; widespread plaque psoriasis; skin conditions with ulcers);
4. Unable to complete informed consent;
5. Pregnancy, breast feeding, or trying to become pregnant.

Study & Design

• Study Type: Interventional
• Study Design: Not specified